Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding
- PMID: 27144051
- PMCID: PMC4837280
- DOI: 10.1155/2016/6461907
Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding
Abstract
A serendipitous pharmacogenetic finding links the vulnerability to developing levodopa-induced dyskinesia to the age of onset of Huntington's disease. Huntington's disease is caused by a polyglutamate expansion of the protein huntingtin. Aberrant huntingtin is less capable of binding to a member of membrane-associated guanylate kinase family (MAGUKs): postsynaptic density- (PSD-) 95. This leaves more PSD-95 available to stabilize NR2B subunit carrying NMDA receptors in the synaptic membrane. This results in increased excitotoxicity for which particularly striatal medium spiny neurons from the indirect extrapyramidal pathway are sensitive. In Parkinson's disease the sensitivity for excitotoxicity is related to increased oxidative stress due to genetically determined abnormal metabolism of dopamine or related products. This probably also increases the sensitivity of medium spiny neurons for exogenous levodopa. Particularly the combination of increased oxidative stress due to aberrant dopamine metabolism, increased vulnerability to NMDA induced excitotoxicity, and the particular sensitivity of indirect pathway medium spiny neurons for this excitotoxicity may explain the observed increased prevalence of levodopa-induced dyskinesia.
Figures


Similar articles
-
Striatal D1 medium spiny neuron activation induces dyskinesias in parkinsonian mice.Mov Disord. 2017 Apr;32(4):538-548. doi: 10.1002/mds.26955. Epub 2017 Mar 3. Mov Disord. 2017. PMID: 28256010 Free PMC article.
-
Postsynaptic density protein 95-regulated NR2B tyrosine phosphorylation and interactions of Fyn with NR2B in levodopa-induced dyskinesia rat models.Drug Des Devel Ther. 2014 Dec 19;9:199-206. doi: 10.2147/DDDT.S75495. eCollection 2015. Drug Des Devel Ther. 2014. PMID: 25565773 Free PMC article.
-
L-DOPA Oppositely Regulates Synaptic Strength and Spine Morphology in D1 and D2 Striatal Projection Neurons in Dyskinesia.Cereb Cortex. 2016 Oct 17;26(11):4253-4264. doi: 10.1093/cercor/bhw263. Cereb Cortex. 2016. PMID: 27613437 Free PMC article.
-
New insights into the mechanism of drug-induced dyskinesia.CNS Spectr. 2013 Feb;18(1):15-20. doi: 10.1017/s1092852912000752. CNS Spectr. 2013. PMID: 23593652 Review.
-
Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity?Ann Neurol. 2000 Apr;47(4 Suppl 1):S60-8; discussion S68-9. Ann Neurol. 2000. PMID: 10762133 Review.
Cited by
-
l-DOPA and Its Receptor GPR143: Implications for Pathogenesis and Therapy in Parkinson's Disease.Front Pharmacol. 2019 Oct 3;10:1119. doi: 10.3389/fphar.2019.01119. eCollection 2019. Front Pharmacol. 2019. PMID: 31632270 Free PMC article. Review.
-
5-Hydroxytryptamine Receptors and Tardive Dyskinesia in Schizophrenia.Front Mol Neurosci. 2020 Apr 24;13:63. doi: 10.3389/fnmol.2020.00063. eCollection 2020. Front Mol Neurosci. 2020. PMID: 32390801 Free PMC article.
-
Study of Early Onset Schizophrenia: Associations of GRIN2A and GRIN2B Polymorphisms.Life (Basel). 2021 Sep 22;11(10):997. doi: 10.3390/life11100997. Life (Basel). 2021. PMID: 34685369 Free PMC article.
-
Effect of Sirt3 on hippocampal MnSOD activity, mitochondrial function, physiology, and cognition in an aged murine model.Behav Brain Res. 2023 Apr 27;444:114335. doi: 10.1016/j.bbr.2023.114335. Epub 2023 Feb 15. Behav Brain Res. 2023. PMID: 36804441 Free PMC article.
References
-
- Birkmayer W., Hornykiewicz O. The L-3,4-dioxyphenylalanine (DOPA)-effect in Parkinson-akinesia. Wiener klinische Wochenschrift. 1961;73(14):787–788. - PubMed
Publication types
LinkOut - more resources
Full Text Sources
Other Literature Sources